Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun;55(6):2992-4.
doi: 10.1128/AAC.01696-10. Epub 2011 Mar 21.

In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study)

A Walkty  1 , M DeCorby, P R S Lagacé-Wiens, J A Karlowsky, D J Hoban, G G Zhanel
Affiliations

In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study)

A Walkty et al. Antimicrob Agents Chemother. 2011 Jun.

Abstract

The in vitro activity of ceftazidime in combination with NXL104 versus 470 Pseudomonas aeruginosa clinical isolates was evaluated using Clinical and Laboratory Standards Institute (CLSI) broth microdilution methods. Ceftazidime had MIC₉₀s of 8 μg/ml and 32 μg/ml in the presence and absence of NXL104, respectively. Of 25 multidrug-resistant P. aeruginosa isolates, the percentages with a ceftazidime MIC of ≤8 μg/ml with and without NXL104 were 60% and 4%, respectively. These data suggest that the ceftazidime-NXL104 combination may prove useful for treating many P. aeruginosa infections.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Number of P. aeruginosa isolates at a given ceftazidime MIC with and without NXL104.
See this image and copyright information in PMC

References

    1. Aloush V., Navon-Venezia S., Seigman-Igra Y., Cabili S., Carmeli Y. 2006. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob. Agents Chemother. 50:43–48 - PMC - PubMed
    1. Biedenbach D. J., Moet G. J., Jones R. N. 2004. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY antimicrobial surveillance program (1997–2002). Diagn. Microbiol. Infect. Dis. 50:59–69 - PubMed
    1. Bonnefoy A., et al. 2004. In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor. J. Antimicrob. Chemother. 54:410–417 - PubMed
    1. Boucher H. W., et al. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1–12 - PubMed
    1. CLSI 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 7th ed CLSI M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA

Publication types

MeSH terms